Entero Therapeutics, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jason David Sawyer
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 777 Yamato Road Boca Raton FL United States of America 33431
- IPO Date
- Oct 11, 2016
- CIK
- 0001604191
- Website
- firstwavebio.com
- Similar Companies
- Business
- Entero Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to the discovery and development of targeted, non-systemic therapies addressing a range of gastrointestinal disorders. The company's pipeline includes latiglutenase, an oral biotherapeutic advancing toward Phase 3 for celiac disease, designed to break down gluten into non-immunogenic fragments. Also in development are capeserod, a selective 5-HT4 receptor partial agonist in Phase 2 for various GI motility issues like gastroparesis, and adrulipase, a recombinant lipase enzyme in Phase 2 for exocrine pancreatic insufficiency, aiming to improve fat digestion for patients with cystic fibrosis and chronic pancreatitis. Beyond its core biopharmaceutical focus, Entero Therapeutics recently made a strategic expansion into AI-driven energy orchestration through its subsidiary, Grid AI Corp., which is developing platforms for optimizing power clusters within hyperscaler AI data centers. The company was formerly known as First Wave BioPharma, Inc., rebranding in May 2024 following its business combination with ImmunogenX. Entero Therapeutics, Inc. was incorporated in 2014 and maintains its headquarters in Boca Raton, Florida.
Entero Therapeutics (NASDAQ:ENTO) Shares Down 3.4% – Should You Sell?
Entero Therapeutics, Inc. Announces Corporate Name Change to GridAI Technologies Corp. and New Ticker Symbol "GRDX"
ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer
Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid
Entero's Reinvention Gives the Grid, AI, and Investors Exactly What They're After: Power and Value (NASDAQ: ENTO)
Entero Regains Nasdaq Compliance With Grid AI Acquisition
Entero Therapeutics, Inc., Launches Grid AI Corp to Redefine How AI Infrastructure Connects to the Power Grid
From Biotech to Grid Tech, Entero Therapeutics Enters a $2.5 Billion Market Expected to Quadruple by 2033 (NASDAQ:ENTO)
Entero Therapeutics Steps Into the $2.5 Billion Grid-Edge Arena With Global-Scale Validation Behind It
Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus
ENTERO THERAPEUTICS (ENTO) Enters $100 Billion+ AI and Data Center Market with Acquisition of GRID AI
ENTERO THERAPEUTICS (ENTO) Acquires 100% of GRID AI, a Grid-Edge AI Platform Optimizing Next-Gen Power Demand
Entero Therapeutics, Inc. Announces Reverse Stock Split
Entero Therapeutics, Inc. Announces $3.0 Million Private Placement Priced at the Market Under Nasdaq Rules
FluroTech Ltd. Announces Change in Directors
Entero Therapeutics Announces Signing of Rescission Agreement with ImmunogenX, LLC
Entero Therapeutics Appoints Richard Paolone as CEO
Entero Therapeutics Secures $2 Million Revolving Loan; Appoints Three New Board Members
$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Entero Therapeutics, Inc. – ENTO